Graviton BioScience Secures FDA IND Clearance for GV101, a Novel ROCK2 Inhibitor for Friedreich's Ataxia
核心洞察
Graviton BioScience received FDA IND clearance on August 7, 2026, for a novel capsule formulation of GV101 targeting Friedreich's ataxia (搜索).
GV101 is a best-in-class selective ROCK2 (搜索) inhibitor that increases frataxin (搜索) protein levels, potentially addressing the root cause of the disease.
A 12-week, randomized, placebo-controlled, dose-finding Phase 2 trial enrolling up to 48 participants is planned to begin in Q1 2027.
Graviton BioScience Corporation announced on August 11, 2026, that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for a novel capsule formulation of GV101, a proprietary oral ROCK2 (搜索) inhibitor being developed for the treatment of Friedreich's ataxia (搜索) (FA). The FDA completed its 30-day review and issued IND clearance on August 7, 2026, marking a critical regulatory milestone that enables Graviton to initiate a Phase 2 clinical study in individuals living with this rare, progressive neurodegenerative disease.
GV101 is described as a best-in-class selective inhibitor of Rho/Rho-associated coiled-coil containing protein kinase 2 (ROCK2 (搜索)), a key regulator of multiple cellular pathways involved in inflammation, fibrosis, metabolism, and gene expression. The new capsule formulation was specifically optimized for development in FA and other potential orphan indications, demonstrating improved pharmacokinetic (PK) properties and oral bioavailability in healthy volunteers during a Phase 1 study.
Mechanism of Action and Preclinical Rationale
Friedreich's ataxia (搜索) is caused by GAA trinucleotide repeat expansions in the FXN gene that result in reduced production of frataxin (搜索), a protein essential for mitochondrial function and cellular energy production. GV101 aims to address this underlying deficiency by increasing frataxin protein levels through selective ROCK2 (搜索) inhibition.
"Our preclinical work has suggested that ROCK2 (搜索) inhibition in cells derived from FA patients increased frataxin (搜索) significantly. ROCK2 inhibition also increased frataxin in PBMCs in patients receiving GV101 in an obesity study. We believe, therefore, that this induction of frataxin by GV101 may become an orally available disease modifying agent," said Rui Wu, Head of Research and Preclinical at Graviton.
Preclinical and clinical studies have demonstrated that GV101 increases both frataxin (搜索) mRNA and protein levels in patient-derived B-lymphocytes and fibroblasts. Consistent with these findings, oral ROCK2 (搜索) inhibition with GV101 increased frataxin levels in vivo in an obesity study that evaluated patient-derived peripheral blood mononuclear cells (PBMCs). Collectively, these results provide evidence that ROCK2 inhibition may increase frataxin expression across multiple experimental systems.
Planned Phase 2 Trial Design
Graviton plans to initiate a 12-week, randomized, placebo-controlled, dose-finding Phase 2 trial enrolling up to 48 participants at multiple sites in the United States and internationally. The study is designed to evaluate the efficacy, safety, and tolerability of a range of GV101 capsule doses in individuals living with Friedreich's ataxia (搜索). The primary endpoint is an increase from baseline in frataxin (搜索) levels measured in patients' cells.
The Phase 2 study will be followed by an open-label extension, offering active drug to all participants who complete the 12-week trial. Participants will be able to continue receiving their existing FDA-approved standard-of-care treatment throughout the study while taking GV101. Enrollment is expected to begin in the first quarter of 2027.
Clinical Experience with GV101
GV101 has demonstrated a favorable safety and tolerability profile across preclinical and clinical studies. More than 500 participants have received GV101 in clinical studies for durations of up to 24 weeks, with extension studies exceeding one year. In a Phase 1 multiple ascending dose study in healthy volunteers, GV101 achieved clinically relevant exposure and demonstrated a favorable safety and tolerability profile.
Disease Background and Unmet Need
Friedreich's ataxia (搜索) affects approximately 5,000 people in the United States and an estimated 15,000 people worldwide, qualifying it as an orphan disease. Symptoms typically begin in childhood or adolescence and worsen over time, affecting coordination, balance, speech, muscle strength, and mobility. Many individuals eventually become wheelchair-dependent and may develop serious complications, including cardiomyopathy, cardiac arrhythmias, diabetes, and difficulties with swallowing and speech. Significant unmet need remains for treatments that address the underlying frataxin (搜索) deficiency that drives the disease.
Increasing frataxin (搜索) protein levels has the potential to move patients toward levels observed in asymptomatic carriers, supporting GV101's potential as a disease-modifying therapy aimed at addressing the underlying cause of Friedreich's ataxia (搜索).